Kansas is most often covered alongside CNBC, which appears in 1 of these 2 stories. Across a 27-day span, the pace is roughly 0.5 stories per week. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Kansas
Kansas is most often covered alongside CNBC, which appears in 1 of these 2 stories. Across a 27-day span, the pace is roughly 0.5 stories per week. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. Their average consequence score of 6.5 runs above the beat's 5.9 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 2 Biotech stories that mention Kansas, published between July 21, 2026 and August 16, 2026.
Stories tracked
2
Per week
0.5
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 174 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Kansas. Shared-story counts are live from our verified record — not editorial picks.
Biotech and pharma teams evaluating cannabinoid-derived drugs face unsettled federal scheduling and reimbursement policy. MMJ's litigation could alter DEA and CMS pathways through stay, remand, or vacatur.
Regulatory chaos after Dobbs is freezing innovation in miscarriage management drugs and devices, delaying emergency care and leaving a $2.3 billion women’s health market in limbo. Vague exceptions in 13 state bans create a minefield for pharma companies developing early pregnancy loss treatments.